Skip to main content

Table 1 Patient characteristics

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Category Subcategory Level 0, N Level -1, N
Total   9 12
Median age (range), yr   78 (74–79) 75 (70–84)
Sex Female 5 7
  Male 4 5
Histological type Adenocarcinoma 8 11
  NSCLC, NOS 1 1
Disease stage IIIB 1 1
  IV 8 10
  Recurrent 0 1
Performance status 0 3 5
  1 6 7
EGFR mutation Ex19 del 0 2
  L858R 2 0
  Wild type 5 7
  Unknown 2 3
  1. EGFR: Epidermal growth factor receptor, Ex19del: Exon 19 deletions, NOS: Not otherwise specified, NSCLC: Non-small-cell lung cancer